Cibus 2025 Q3 Earnings Significant Loss Reduction as Net Income Narrows by 87.9%

Cibus (CBUS) reported fiscal 2025 Q3 earnings on Nov 14, 2025, with revenue declining 63.1% to $615,000 versus $1.67 million in 2024 Q3. While the company missed revenue estimates, it significantly narrowed losses to $0.44 per share (a 94.2% improvement from $7.63 per share in 2024 Q3) and reduced net losses by 87.9% to $24.3 million from $201.5 million. The stock dropped 5.30% in the latest trading day and 14.97% month-to-date, reflecting ongoing market skepticism.

Revenue

Total revenue for Q3 2025 fell sharply to $615,000, a 63.1% decline from $1.67 million in the prior-year period. The reduction primarily reflects timing of partner-funded program activities, as noted in the company’s financial report. Despite this, Cibus has secured seven rice customer agreements covering 5–7 million addressable acres, with potential annual royalty revenue exceeding $200 million.

Earnings/Net Income

Cibus narrowed its per-share loss to $0.44 in Q3 2025 from $7.63 in Q3 2024, marking a 94.2% improvement. The net loss itself dropped to $24.3 million, a 87.9% reduction from $201.5 million in the prior year. While the EPS remains negative, the magnitude of the improvement underscores progress in cost management and operational efficiency.

Post-Earnings Price Action Review

The strategy of buying Cibus shares on the date of its revenue release and holding for 30 days yielded negative returns over the past three years, with an annualized return of -23.2% and a total loss of 68.4%. This indicates the strategy was not profitable for CBUS.

CEO Commentary

Peter Beetham, Interim CEO, highlighted advancements in rice herbicide tolerance (HT1/HT3) commercialization, including seven signed customer agreements and partnerships in Latin America and India. The company also advanced HT2 Canola trials and pre-commercial biofragrance pilots, while operational efficiency initiatives aim to reduce annual cash usage to $30 million by 2026.

Guidance

Cibus expects to deliver HT traits to Latin American customers by Q4 2025, with field trials commencing by year-end. Commercial biofragrance expansion is targeted for 2026, and the company anticipates regulatory progress for HT2 Canola in 2025. Cash resources are projected to fund operations into early Q2 2026.

Additional News

Cibus strengthened its board with the appointments of Kimberly Box and Craig Wisner, bringing expertise in technology operations and sustainable agriculture. The company also completed pre-commercial biofragrance pilot runs and secured regulatory approval for gene-edited rice planting in California. Additionally, Cibus reduced operating expenses by $5 million in the first nine months of 2025, extending its cash runway.